使用剂量升级和扩展队列研究作为针对性抗癌药物批准的关键试验
Yafang Huang1, Ting Zhu1, Jinjia Zhong1
1School of General Practice and Continuing Education, Capital Medical University, Beijing, China.
JCO precision oncology
|August 1, 2025
概括
剂量升级和扩展队列 (DEEC) 试验通过减少时间和资源来加快新型抗癌药物的批准. 审查DEEC的设计,实施和分析可以提高证据质量,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 临床试验设计 临床试验设计
- 药物开发 药物开发
背景情况:
- 早期临床试验 (EPCT) 对于FDA批准新型抗癌药物至关重要.
- 剂量升级和扩展队列 (DEEC) 设计简化了传统的多阶段试验.
- DEEC加速了针对性治疗的可用性,以满足未满足需求的患者.
研究的目的:
- 分析DEEC试验的设计,进行和分析.
- 确定DEEC研究的优点和局限性.
- 提高DEEC试验产生的临床证据的质量.
主要方法:
- 在DEEC试验设计和进行中审查结构领域和项目.
- 对剂量升级方法的分析 (例如,3+3,BOIN,CRM).
- 检查灵活的扩展队列设计 (例如,篮子,雨,平台) 和适应性方法 (例如,西蒙的两阶段).
主要成果:
- 在2012-2023年期间,DEEC支持FDA批准46种适用于36种向抗癌药物的46种适用症.
- 对于剂量升级和扩张阶段,采用了各种统计方法.
- 终点判断对于减轻DEEC试验中的偏见至关重要.
结论:
- DEEC试验为抗癌药物开发提供了一个有效的范式.
- 在DEEC报告中解决被忽视的特征对于产生强有力的证据至关重要.
- 优化DEEC的利用可以改善临床证据和患者的治疗结果.
更多相关视频
相关概念视频
Clinical Trials: Overview
3.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Dose-Response Relationship: Potency and Efficacy
5.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.2K


